Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.

ISR Immune System Regulation

Alle 1K seuraajaa

Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.

Yksityisyysasetukset

ISR Immune System Regulation

ISR Immune System Regulation

ISR's, SARS-CoV-2 dry powder nasal - vaccine booster candidate, ISR52, demonstrates superior immune response, in mouse model challenge studies compared to subcutaneous injection of this vaccine.

ISR, Audiocast with teleconference, Half-year report 2022

ISR: SARS-CoV-2 vaccine study approved by Bangladesh BMRC

Liity Inderesin yhteisöön

FREE-tili

PREMIUM-tili

ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccine, powder formulation for Phase III.

ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccine, powder formulation for Phase III.

Delegation from Bangladesh visits ISR for study preparation

Redeye: Redeye Initiates Coverage of ISR Holding

ISR, Audiocast with teleconference, Year-end Report, 2021

ISR's, SARS-CoV-2 dry powder nasal - vaccine booster candidate, ISR52, demonstrates superior immune response, in mouse model challenge studies compared to subcutaneous injection of this vaccine.

ISR, Audiocast with teleconference, Half-year report 2022

ISR: SARS-CoV-2 vaccine study approved by Bangladesh BMRC

Liity Inderesin yhteisöön

FREE-tili

PREMIUM-tili

ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccine, powder formulation for Phase III.

ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccine, powder formulation for Phase III.

Delegation from Bangladesh visits ISR for study preparation

Redeye: Redeye Initiates Coverage of ISR Holding

ISR, Audiocast with teleconference, Year-end Report, 2021